Gefitinib is a targeted therapy drug used primarily for the treatment of certain types of non-small cell lung cancer (NSCLC). It is classified as an epidermal growth factor receptor (EGFR) inhibitor, which means it targets and blocks the activity of the EGFR protein on the surface of cancer cells.
